Shire Plc American Depositary Shares (SHPG) 253.58

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Shire Plc American Depositary Shares (SHPG) 253.58 $SHPG

Hedge fund honcho eyes Biogen patent covering top-selling Tecfidera
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 3:04PM CDT

BIIB: 423.57 (+1.46), SHPG: 253.58 (+3.70), ACOR: 33.34 (-1.33)

Abbott Labs (ABT) Beats on Q1 Earnings, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 12:18PM CDT
Abbott Laboratories (ABT) reported first-quarter 2015 earnings of 47 cents per share, up 38.2% from the year-ago quarter and beat the Zacks Consensus Estimate of 42 cents.
ABT: 48.35 (+1.23), VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), MYL: 72.40 (-1.67)

3 Large-Cap Pharmaceutical Companies to Invest in Right Now
at The Street - Wed Apr 22, 8:23AM CDT
Pharmaceutical companies can be a huge risk for investors -- but if the risks pay off, the rewards can be huge.
NVO: 56.37 (-0.17), SHPG: 253.58 (+3.70), RDY: 56.58 (+0.30)

Gilead Sciences Vs. AbbVie: Which Is A Better Buy?
Mycroft - at Seeking Alpha - Wed Apr 22, 7:49AM CDT

JNJ: 100.43 (+0.13), ABT: 48.35 (+1.23), PCYC: 256.98 (-0.77), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ABBV: 64.52 (+0.91)

Seattle Genetics' Adcetris Under Review for New Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:07PM CDT
Seattle Genetics, Inc.'s (SGEN) supplemental BLA for Adcetris has been accepted by the FDA for priority review as consolidation therapy in the post-transplant setting.
SGEN: 36.92 (-0.32), SHPG: 253.58 (+3.70), HZNP: 30.96 (+0.10), BMY: 66.60 (-0.21)

Merck KGaA-Pfizer Start First Cancer Registration Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:50PM CDT
Merck KGaA (MKGAF) and Pfizer Inc. (PFE) announced the commencement of a phase III study on avelumab in comparison with Taxotere for non-small cell lung cancer.
SHPG: 253.58 (+3.70), PFE: 34.93 (+0.04), HZNP: 30.96 (+0.10)

Ampio Plunges as STRIDE Study on Ampion Fails - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 11:48AM CDT
Ampio Pharmaceuticals, Inc. (AMPE) announced disappointing results from the multiple injection STRIDE study AP008 on pipeline candidate Ampion.
VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), ARQL: 2.11 (-0.03), AMPE: 2.89 (+0.20)

Genzyme starts mid-stage trial of oral Fabry disease therapy
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 10:34AM CDT

SHPG: 253.58 (+3.70), PLX: 2.08 (+0.02), SNY: 51.59 (+0.03), FOLD: 11.97 (-0.35)

Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
M2 - Mon Apr 20, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w97ksb/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering. The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019 Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS. Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price. According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups. Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population. Key Vendors - Alexion Pharmaceuticals - Amgen - Celgene - F. Hoffmann- La Roche - GlaxoSmithKline - Incyte Other Prominent Vendors - Cyclacel Pharmaceuticals - CTI Biopharma (Cell Therapeutics) - Eli Lilly - Gilead Sciences - Onconova Therapeutics - MebVax Therapeutics - Novartis - Sanofi - Shire Pharmaceuticals - S* Bio Pte For more information visit http://www.researchandmarkets.com/research/w9...l_acquired
CYCC: 0.94 (-0.03), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ONTX: 2.48 (-0.05), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)

This New Hedge Fund Strategy Just Might Be Crazy Enough To Work
Matthew Frankel, The Motley Fool - Motley Fool - Sun Apr 19, 1:07PM CDT
Hedge funds use a lot of strategies to make money, but one manager is doing something we've never seen before in order to make a profit -- challenging a company's patents and shorting its stock simultaneously. How exactly does it work, and will it...
SHPG: 253.58 (+3.70), JAZZ: 186.13 (-0.41), ACOR: 33.34 (-1.33)

Will This Hedge Fund Manager Bring Down Your Biotech Stocks?
Selena Maranjian, The Motley Fool - Motley Fool - Sun Apr 19, 12:01PM CDT
Hedge-fund manager Kyle Bass. Image: Insider Monkey Many hedge-fund managers are "activist" ones. They load up on stock in particular companies until they have so many shares that they can put pressure on management to take actions they...
SHPG: 253.58 (+3.70), JAZZ: 186.13 (-0.41), ACOR: 33.34 (-1.33)

4 Big Biopharma Deals We Might See In 2015
Sy Mukherjee - Seeking Alpha - Thu Apr 16, 1:29PM CDT
In 2000, UK-based Glaxo Wellcome joined forces with SmithKline Beecham in a $74 billion merger that birthed the global pharma giant GlaxoSmithKline (NYSE: GSK ). It was, far and away, the biggest biopharma deal of the year. What a difference 14...
BMRN: 121.08 (-0.16), PCYC: 256.98 (-0.77), PFE: 34.93 (+0.04), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), HSP: 87.80 (+0.04), CELG: 115.54 (+0.72), SGEN: 36.92 (-0.32), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), AZN: 73.35 (+0.65), JAZZ: 186.13 (-0.41), MRK: 57.69 (+0.03), ABBV: 64.52 (+0.91)

Goldman's Monster Q1 Spurred By Megadeals, Volatility
at Investor's Business Daily - Thu Apr 16, 10:32AM CDT
Goldman Sachs (GS) crushed Wall Street's first-quarter expectations, as stock market volatility fueled trading revenue and a string of megadeals boosted advisory fees. The investment banking giant earned $5.94 a share, up 47.8% from a year earlier...
GS: 198.32 (+1.48), JPM: 62.94 (+0.63), C: 53.10 (+0.62), SHPG: 253.58 (+3.70), BAC: 15.74 (+0.24), WFC: 54.67 (+0.39), MS: 37.20 (+0.45)

Cardiomyopathy Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Wed Apr 15, 1:20PM CDT
The report "Cardiomyopathy - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Cardiomyopathy. Cardiomyopathy, any cardiac disease process that results in heart failure due to a decrease in the pumping power of the heart or due to an impairment in the filling of the cardiac chambers. Types of Cardiomyopathy are ischemic, dilated, hypertrophic and restrictive Cardiomyopathy. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cardiomyopat...eport.html .
GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), CLDN: 13.59 (-2.77), NVS: 103.45 (-0.62)

Analyzing The FTSE 100 For Opportunities
Nick Mackintosh - at Seeking Alpha - Mon Apr 13, 10:05PM CDT

BTI: 112.59 (+0.32), ARMH: 54.07 (+0.47), SHPG: 253.58 (+3.70)

Goldman's Q1 Seen Lifted By Gyrating Stocks, Big M&A
at Investor's Business Daily - Mon Apr 13, 4:26PM CDT
The volatile stock market and heavier trading volumes should translate into a good first quarter for Goldman Sachs (GS), which also should receive a boost from its financial advisory unit thanks to Q1's strong M&A activity. When it reports results on...
GS: 198.32 (+1.48), JPM: 62.94 (+0.63), SHPG: 253.58 (+3.70), MS: 37.20 (+0.45)

CNS Therapeutics - Global Strategic Business Report 2015-2020
M2 - Mon Apr 13, 4:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ht282w/cns_therapeutics) has announced the addition of the "CNS Therapeutics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 145 companies including many key and niche players such as: - AbbVie Inc. (USA) - Actavis Plc. (Ireland) - Alkermes Plc. (Ireland) - Amneal Pharmaceuticals, LLC (USA) - Aspen Pharmacare Holdings Limited (Australia) - AstraZeneca Plc (UK) - BIAL Group (Portugal) - Boehringer Ingelheim GmbH (Germany) - Bristol-Myers Squibb (USA) - Dainippon Sumitomo Pharma Co., Ltd. (Japan) - Eisai Co., Ltd. (Japan) - Eli Lilly and Co. (USA) - F. Hoffmann-La Roche Ltd. (Switzerland) - Fabre-Kramer Pharmaceuticals, Inc. (USA) - GlaxoSmithKline (UK) - H. Lundbeck A/S (Denmark) - Johnson & Johnson (USA) - Janssen Pharmaceuticals, Inc. (USA) - Merck & Co., Inc. (USA) - Neurocrine Biosciences, Inc. (USA) - Novartis AG (Switzerland) - Otsuka Pharmaceutical Co., Ltd. (Japan) - Pfizer, Inc. (USA) - Sanofi S.A (France) - Shire Plc (UK) - Sunovion Pharmaceuticals, Inc. (USA) - Takeda Pharmaceutical Co., Ltd. (Japan) - Teva Pharmaceutical Industries Ltd. (Israel) - UCB Group (Belgium) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. NOTEWORTHY MARKET TRENDS, GROWTH DRIVERS & ISSUES 3. MARKET ANALYSIS BY THERAPEUTIC CATEGORIES 4. PRODUCT OVERVIEW 5. PRODUCT INTRODUCTIONS/INNOVATIONS & R&D BREAKTHROUGHS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 145 (including Divisions/Subsidiaries - 172) - The United States (69) - Canada (11) - Japan (14) - Europe (47) - - France (4) - - Germany (9) - - The United Kingdom (11) - - Italy (1) - - Rest of Europe (22) - Asia-Pacific (Excluding Japan) (23) - Middle East (7) - Africa (1) For more information visit http://www.researchandmarkets.com/research/ht...erapeutics
PFE: 34.93 (+0.04), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), ALKS: 62.60 (-0.24), JNJ: 100.43 (+0.13), NBIX: 43.23 (-0.43), SHPG: 253.58 (+3.70), AZN: 73.35 (+0.65), MRK: 57.69 (+0.03), TEVA: 63.01 (-1.15), ABBV: 64.52 (+0.91), NVS: 103.45 (-0.62)

Shire's SHP625 Fails in Phase II, FDA Accepts Lifitegrast NDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 4:26PM CDT
Shire plc (SHPG) announced disappointing results from the phase II trial IMAGO on pipeline candidate SHP625 (formerly LUM001).
ACT: 295.22 (+0.69), VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), ARQL: 2.11 (-0.03)

Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 423.57 (+1.46), SPHS: 0.82 (+0.01), ADMS: 17.62 (-0.21), TKMR: 18.38 (-0.14), CBYL: 7.02 (-0.38), HPTX: 45.96 (-0.18), QURE: 26.15 (-1.44), SHPG: 253.58 (+3.70), SRPT: 13.52 (+0.04), HZNP: 30.96 (+0.10), GALE: 1.39 (unch), JUNO: 55.72 (-0.68), ABBV: 64.52 (+0.91), CBMG: 32.14 (+2.21), ARNA: 4.47 (+0.01), EXEL: 3.12 (+0.05), ADXS: 22.18 (+0.10), PTLA: 38.48 (-0.47), BMY: 66.60 (-0.21), OCUL: 25.90 (-0.05), NVO: 56.37 (-0.17), DVA: 83.22 (+0.10), HALO: 16.03 (+0.15), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), ALXN: 188.19 (+1.41), NVS: 103.45 (-0.62)

Critical Alerts For GoPro, Shire, Isis Pharmaceuticals, Whiting Petroleum and athenahealth Released By InvestorsObserver
PR Newswire - Fri Apr 10, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, SHPG, ISIS, WLL and ATHN.
GPRO: 46.25 (+1.94), WLL: 36.12 (+1.16), ISIS: 66.26 (-0.03), SHPG: 253.58 (+3.70), ATHN: 120.16 (-1.35)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 193

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Mudrick Urges Doncasters to Test a Strategic Sale Now

Updated Category News Views 0

Castings are rarely glamorous until nobody can get them, and Mudrick Capital is betting that ugly little industrial reality could make Doncasters worth far more in a takeover than the market currently credits. The event-driven investor, which says it owns roughly 4.3% of DPC Holdings Limited, has asked the board to quietly evaluate strategic alternatives, including a sale...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 125

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 102

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 67

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 48

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 55

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 131

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading

Top 5 Most Recently Viewed Articles

BioMarin's Strong 2024 Performance Fuels 2025 Expectations

Updated Category News Views 392

BioMarin's Empowering Growth Journey Into 2025 BioMarin Pharmaceutical Inc. has marked a significant achievement with its record performance in 2024, setting a strong foundation for the upcoming year. The company demonstrated robust operational execution and is gearing up for a year of potential double-digit revenue growth as it advances its corporate strategy focusing on...

Continue Reading
Berkshire Hills Bancorp Declares Cash Dividend for Shareholders

Updated Category News Views 104

Berkshire Hills Bancorp Announces Quarterly Dividend Berkshire Hills Bancorp, Inc. (NYSE: BHLB) has recently declared a quarterly cash dividend of $0.18 per common share for its shareholders. This decision by the Board of Directors aims to reward shareholders who are on record by a specified date. Details of the Dividend Announcement The approved cash dividend will be...

Continue Reading
Maiden United Transforms Adele's Skyfall into Heavy Metal Epic

Updated Category News Views 167

Maiden United Transforms Iconic Adele Song into Heavy Metal What if Iron Maiden had recorded the legendary James Bond theme song? Maiden United, a notable tribute band dedicated to Iron Maiden, has taken that intriguing concept and turned it into reality. The band has just unveiled their latest EP entitled Agent 666, which features an electrifying heavy metal cover of...

Continue Reading
Cherokee Federal Boosts Growth with MSI, LLC Investment

Updated Category News Views 213

Cherokee Federal Expands Presence Through Strategic Investment Cherokee Federal, a division of Cherokee Nation Businesses (CNB), has recently announced a significant move in the federal contracting realm. They have acquired a majority stake in Management Science and Innovation, LLC, also known as MSI. This strategic investment marks another milestone under their...

Continue Reading
Metallurgical Coal Market Expected Growth Amid Steel Demand Spike

Updated Category News Views 125

Growth of the Metallurgical Coal Market The global metallurgical coal market is poised for significant growth, estimated at USD 95.27 billion from 2024 to 2028. This growth is largely driven by the increasing demand for steel, which is essential for numerous infrastructure projects around the world. As smart city developments surge, the necessity for high-quality steel...

Continue Reading